Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled induction study of oral ozanimod in moderate to severe active Crohn's disease
MOH_2018-10-02_003662Phase 3Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Ozanimod with Placebo (2 arms). Planned start Aug 2018; status: not yet recruiting.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2018-10-02_003662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-10-02_003662.